Trial Outcomes & Findings for A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (NCT NCT03073525)

NCT ID: NCT03073525

Last Updated: 2023-04-05

Results Overview

The safety evaluation included Adverse Events (AEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs) and changes from baseline in laboratory evaluations, vital signs, electrocardiograms and physical examinations. AEs were graded according to the National Cancer Institute (NCI) CTCAE v4.03 and coded using the Medical Dictionary for Regulatory Activities. Laboratory abnormalities were graded according to the NCI CTCAE v4.03, if applicable.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 25 participants
• Primary outcome timeframe: AEs reported from first treatment dose and up to 30 days after last treatment, about 12 months.
• Results posted on: 2023-04-05

Participant Flow

Twenty-five (25) subjects signed the informed consent to enter the treatment portion of the trial. One (1) subject was ineligible, and a total of 24 subjects received treatment in the study.

Participant milestones

Measure	Part 1: Vigil + Atezo This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo After Part 1 participants completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to Vigil first received two cycles of Vigil alone, then Vigil and atezolizumab given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. Participants who completed all cycles of Part 2 were pre-approved by the sponsor for inclusion into Part 3. Atezolizumab alone was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo After Part 1 participants completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to atezolizumab first received two cycles of atezolizumab alone, then Vigil and atezolizumab given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. Participants who completed all cycles of Part 2 were pre-approved by the sponsor for inclusion into Part 3. Atezolizumab alone was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days
Overall Study STARTED	3	11	10
Overall Study Part 3: Atezolizumab Alone	0	1	0
Overall Study COMPLETED	3	11	7
Overall Study NOT COMPLETED	0	0	3

Reasons for withdrawal

Measure	Part 1: Vigil + Atezo This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo After Part 1 participants completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to Vigil first received two cycles of Vigil alone, then Vigil and atezolizumab given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. Participants who completed all cycles of Part 2 were pre-approved by the sponsor for inclusion into Part 3. Atezolizumab alone was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo After Part 1 participants completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to atezolizumab first received two cycles of atezolizumab alone, then Vigil and atezolizumab given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. Participants who completed all cycles of Part 2 were pre-approved by the sponsor for inclusion into Part 3. Atezolizumab alone was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. 1 cycle = 21 days
Overall Study Withdrawal by Subject	0	0	3

Baseline Characteristics

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Baseline characteristics by cohort

Measure	Part 1: Vigil + Atezo n=3 Participants This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo n=11 Participants After Part 1 participants completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to Vigil first received two cycles of Vigil alone, then Vigil and atezolizumab given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo n=10 Participants After Part 1 participants completed combination therapy without dose-limiting toxicity, then Part 2 participants randomized to atezolizumab first received two cycles of atezolizumab alone, then Vigil and atezolizumab given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Total n=24 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Categorical Between 18 and 65 years	2 Participants n=5 Participants	5 Participants n=7 Participants	7 Participants n=5 Participants	14 Participants n=4 Participants
Age, Categorical >=65 years	1 Participants n=5 Participants	6 Participants n=7 Participants	3 Participants n=5 Participants	10 Participants n=4 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	11 Participants n=7 Participants	10 Participants n=5 Participants	24 Participants n=4 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants
Race (NIH/OMB) White	3 Participants n=5 Participants	9 Participants n=7 Participants	8 Participants n=5 Participants	20 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Region of Enrollment United States	3 participants n=5 Participants	11 participants n=7 Participants	10 participants n=5 Participants	24 participants n=4 Participants
Number of Prior Lines of Systemic Therapies 1	0 Participants n=5 Participants	5 Participants n=7 Participants	2 Participants n=5 Participants	7 Participants n=4 Participants
Number of Prior Lines of Systemic Therapies 2	1 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	8 Participants n=4 Participants
Number of Prior Lines of Systemic Therapies 3	1 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	7 Participants n=4 Participants
Number of Prior Lines of Systemic Therapies 4	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants
Baseline ECOG 0	2 Participants n=5 Participants	7 Participants n=7 Participants	2 Participants n=5 Participants	11 Participants n=4 Participants
Baseline ECOG 1	1 Participants n=5 Participants	4 Participants n=7 Participants	8 Participants n=5 Participants	13 Participants n=4 Participants

PRIMARY outcome

Timeframe: AEs reported from first treatment dose and up to 30 days after last treatment, about 12 months.

Population: Grade 3/4 treatment-related events from first dose up to 30 days after last treatment.

The safety evaluation included Adverse Events (AEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs) and changes from baseline in laboratory evaluations, vital signs, electrocardiograms and physical examinations. AEs were graded according to the National Cancer Institute (NCI) CTCAE v4.03 and coded using the Medical Dictionary for Regulatory Activities. Laboratory abnormalities were graded according to the NCI CTCAE v4.03, if applicable.

Outcome measures

Measure	Part 1: Vigil + Atezo n=3 Participants This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo n=11 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if Vigil given first then combined with atezolizumab would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo n=10 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if atezolizumab given first then combined with Vigil would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days
Number of Treatment-emergent AEs of Vigil + Atezolizumab Grade 4 Atezolizumab-Related	0 adverse events	0 adverse events	0 adverse events
Number of Treatment-emergent AEs of Vigil + Atezolizumab Grade 4 Vigil-Related	0 adverse events	0 adverse events	0 adverse events
Number of Treatment-emergent AEs of Vigil + Atezolizumab Grade 3 Atezolizumab-Related	0 adverse events	1 adverse events	4 adverse events
Number of Treatment-emergent AEs of Vigil + Atezolizumab Grade 3 Vigil-Related	0 adverse events	0 adverse events	0 adverse events

SECONDARY outcome

Timeframe: Up to 30 days after last treatment

Population: Samples were not analyzed for immune response data.

Whole blood for correlative studies will be obtained at baseline, at the start of cycle 3 (the first cycle of combination therapy), every 3 cycles thereafter and end of treatment.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From baseline (prior to treatment) up to 3 years

Population: All treated participants

Overall assessment of time to progression and survival will be measured by Radiological Tumor Assessment by local investigators using the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

In Part 1, disease progression was assessed at baseline and every third cycle thereafter. In Part 2, the disease was assessed at baseline, at the end of Cycle 2 of single-agent therapy, and every third cycle thereafter.

Outcome measures

Measure	Part 1: Vigil + Atezo n=3 Participants This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo n=11 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if Vigil given first then combined with atezolizumab would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo n=10 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if atezolizumab given first then combined with Vigil would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days
Time to Progression	3.42 months Interval 1.61 to Not Reached	3.42 months Interval 3.3 to Not Reached	2.86 months Interval 2.5 to Not Reached

SECONDARY outcome

Timeframe: From first dose to end of study treatment (up to 9 months)

Population: All treated participants

Radiographic ORR is defined as the percentage of participants achieving a Complete Response (CR) or Partial Response (PR), as assessed by investigators using RECIST 1.1.

In Part 1, ORR was assessed at baseline and every third cycle thereafter. In Part 2, the disease was assessed at baseline, at the end of Cycle 2 of single-agent therapy, and every third cycle thereafter.

95% confidence interval from exact binomial distribution (Blopper-Pearson method).

Outcome measures

Measure	Part 1: Vigil + Atezo n=3 Participants This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo n=11 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if Vigil given first then combined with atezolizumab would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo n=10 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if atezolizumab given first then combined with Vigil would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days
Radiographic Overall Response Rate (ORR)	33 percentage of participants with response Interval 0.8 to 90.6	9 percentage of participants with response Interval 0.2 to 41.3	10 percentage of participants with response Interval 0.03 to 44.5

SECONDARY outcome

Timeframe: OS will be evaluated from time of randomization up to 37 months following documented disease progression.

Population: All treated participants.

OS is defined as time of randomization to date of death due to any cause.

Outcome measures

Measure	Part 1: Vigil + Atezo n=3 Participants This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil Then Vigil + Atezo n=11 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if Vigil given first then combined with atezolizumab would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 2: Atezo Then Vigil + Atezo n=10 Participants Patients in Part 1 completed combination therapy without dose-limiting toxicity justifying expansion to Part 2. This arm was to determine if atezolizumab given first then combined with Vigil would enhance immunotherapeutic anticancer activity. Overall, efficacy of administration sequence was assessed. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. When Vigil and atezolizumab was given together, Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days
Overall Survival (OS)	8.2 Months Interval 5.78 to Not enough patients have had an event	37.0 Months Interval 18.5 to Not enough patients have had an event	15.1 Months Interval 5.22 to Not enough patients have had an event

Adverse Events

Part 1: Vigil + Atezo

Serious events: 2 serious events

Other events: 2 other events

Deaths: 3 deaths

Part 2: Vigil

Serious events: 2 serious events

Other events: 9 other events

Deaths: 2 deaths

Part 2: Atezo

Serious events: 4 serious events

Other events: 10 other events

Deaths: 3 deaths

Part 2: Vigil and Atezo

Serious events: 1 serious events

Other events: 15 other events

Deaths: 9 deaths

Part 3: Atezo

Serious events: 0 serious events

Other events: 1 other events

Deaths: 1 deaths

Serious adverse events

Measure	Part 1: Vigil + Atezo n=3 participants at risk This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil n=11 participants at risk Part 2 participants randomized to Vigil first received Vigil immunotherapy at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection for the first two cycles. 1 cycle = 21 days	Part 2: Atezo n=10 participants at risk Part 2 participants randomized to atezolizumab first received atezolizumab at a dose of 1200 mg as an intravenous infusion for the first two cycles. 1 cycle = 21 days	Part 2: Vigil and Atezo n=21 participants at risk After Part 2 participants completed the first two cycles of Vigil or atezolizumab, then Vigil and atezolizumab was given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 3: Atezo n=1 participants at risk Participants continue on single agent atezolizumab until disease progression. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion. 1 cycle = 21 days.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Abdominal Pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Ascites	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Fever	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Small Bowel Obstruction	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Partial Small Intestinal Obstruction	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Weakness	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations Increased Creatinine	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Injury, poisoning and procedural complications Infusion Reaction	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Vascular disorders Thromboembolic Event	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders TIA	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.

Other adverse events

Measure	Part 1: Vigil + Atezo n=3 participants at risk This was a safety run in and intervention was combined. The first three participants received Vigil immunotherapy at a concentration of 1x10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days.	Part 2: Vigil n=11 participants at risk Part 2 participants randomized to Vigil first received Vigil immunotherapy at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection for the first two cycles. 1 cycle = 21 days	Part 2: Atezo n=10 participants at risk Part 2 participants randomized to atezolizumab first received atezolizumab at a dose of 1200 mg as an intravenous infusion for the first two cycles. 1 cycle = 21 days	Part 2: Vigil and Atezo n=21 participants at risk After Part 2 participants completed the first two cycles of Vigil or atezolizumab, then Vigil and atezolizumab was given in sequence. Vigil immunotherapy was administered at a concentration of 1 x 10e6 or 1 x 10e7 cells/dose given via intradermal injection every 3 weeks for a minimum of 4 doses and a maximum of 12 doses. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion every 3 weeks, with a maximum of 12 doses. Vigil was administered first, followed 30 minutes later by atezolizumab. 1 cycle = 21 days	Part 3: Atezo n=1 participants at risk Participants continue on single agent atezolizumab until disease progression. Atezolizumab was administered at a dose of 1200 mg as an intravenous infusion. 1 cycle = 21 days.
Blood and lymphatic system disorders Anemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 6 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 5 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Blood and lymphatic system disorders Leukopenia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Cardiac disorders Tachycardia	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Cardiac disorders Atrial fibrillation	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Ear and labyrinth disorders Hearing impaired	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Endocrine disorders Goiter nodular	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Endocrine disorders Hypothyroidism	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Eye disorders Dry eyes	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Abdominal distension	33.3% 1/3 • Number of events 5 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Abdominal pain	66.7% 2/3 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	33.3% 7/21 • Number of events 8 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Ascites	33.3% 1/3 • Number of events 5 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Constipation	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Diarrhea	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	27.3% 3/11 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Gastrointestinal discomfort	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Hemorrhoidal hemorrhage	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Mucositis oral	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Nausea	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	63.6% 7/11 • Number of events 8 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	19.0% 4/21 • Number of events 6 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Oral pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	100.0% 1/1 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Sore mouth	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Swallowing difficult	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Toothache	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Gastrointestinal disorders Vomiting	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Axillary pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Edema extremities	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Fatigue	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	30.0% 3/10 • Number of events 6 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	33.3% 7/21 • Number of events 7 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Fever	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Flu like symptoms	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	19.0% 4/21 • Number of events 4 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Heat intolerance	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Injection site reaction	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
General disorders Pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Infections and infestations Acute cystitis	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Infections and infestations Thrush	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Infections and infestations Urinary tract infection	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Injury, poisoning and procedural complications Incision site pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	100.0% 1/1 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations ALT increased	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations AST increased	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations BUN increased	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations Carbon dioxide decreased	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations Creatinine increased	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 6 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations Lymphocyte count decreased	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations ST segment elevated	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Investigations Weight loss	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Acidemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Anorexia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hypercholesterolemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hyperglycemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hyperkalemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hypoalbuminemia	33.3% 1/3 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hypocalcemia	33.3% 1/3 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hypokalemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hyponatremia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Metabolism and nutrition disorders Hypophosphatemia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Jaw pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	100.0% 1/1 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Muscle cramps	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 4 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Dizziness	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Dysgeusia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Headache	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	20.0% 2/10 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Intermittent headache	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Paresthesia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Peripheral neuropathy	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.5% 2/21 • Number of events 4 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Psychiatric disorders Anxiety reaction	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Psychiatric disorders Depression	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Renal and urinary disorders Acute kidney injury	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Renal and urinary disorders Chronic kidney disease	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Renal and urinary disorders Nephritis	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Renal and urinary disorders Urinary frequency	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Reproductive system and breast disorders Pelvic pain	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Aspiration pneumonia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Allergic rhinitis	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Dry cough	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 4 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Dyspnea	33.3% 1/3 • Number of events 3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	18.2% 2/11 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	40.0% 4/10 • Number of events 4 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	14.3% 3/21 • Number of events 5 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Dyspnea exertional	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	10.0% 1/10 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Pleural effusion	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	100.0% 1/1 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Skin and subcutaneous tissue disorders Itching	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	9.1% 1/11 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 2 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Respiratory, thoracic and mediastinal disorders Pruritus	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Vascular disorders Hot flashes	33.3% 1/3 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/21 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.
Vascular disorders Lymphedema	0.00% 0/3 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/11 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/10 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	4.8% 1/21 • Number of events 1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.	0.00% 0/1 • SAEs and Other Adverse Events: Adverse events were recorded from time of first dose of Vigil and/or atezolizumab up to 30 days following the last dose of study treatment or until another therapy was initiated (up to 12 months). All-cause Mortality: from randomization and up to 37 months following disease progression. All treated participants.

Additional Information

Clinical and Regulatory Operations

Gradalis, Inc

Phone: 214-442-8100

Email: info@gradalisinc.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place